CHEK2 and neoplasm: Their analysis of 4008 cases with 13 tumor types and 4000 controls found a moderately increased risk of breast, prostate, and thyroid cancer in carriers of truncating CHEK2 mutations and an increased risk of breast, colon, kidney, prostate, and thyroid cancer for the carriers of p.I157T.